Back to Newsroom

All Physicians in Switzerland Are Now Able to Prescribe Sucampo’s AMITIZA(R) for Chronic Idiopathic Constipation

Swiss Bundesamt fur Gesundheit (BAG) Lifts Several Key Restrictions to AMITIZA Specialty List, Increasing Patient Access

BETHESDA, Md., Feb. 6, 2014 — Sucampo AG (“SAG”), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) (“Sucampo”), headquartered in Zug, Switzerland, announced today that all physicians in Switzerland are now able to prescribe AMITIZA® (lubiprostone) for chronic idiopathic constipation (CIC), as a result of the revision of the reimbursement limitations by the Bundesamt für Gesundheit (BAG), effective February 1, 2014.